Outcome of silicone intubation for occluded lacrimal passage secondary to treatment with TS-1® Shuichiro Sasaki 1 , Masahide Kokado 1 , Yukihisa Takada 1 , Shizuya Saika 1 1Department of Ophthalmology, Wakayama Medical University pp.765-769
Published Date 2020/6/15
DOI https://doi.org/10.11477/mf.1410213594
  • Abstract
  • Look Inside
  • Reference

Abstract Background:TS-1® is an anticancer drug and contains tegafur, gimeracil, and oteracil kalium. Occlusion of nasolacrimal system is regarded as one of its complications.

Purpose:To report the outcome of silicone intubation for obstructed lacrimal passage obstruction following treatment with TS-1® in the past 66 months.

Cases and Method:We reviewed 10 patients who received silicone intubation for lacrimal passage obstruction following treatment with TS-1®. All the 10 cases were males. The age averaged 68.0±8.9 years. Two cases were unilaterally and 8 were bilaterally affected, resulting in 18 affected sides.

Results:Out of 18 affected sides, lacrimal canaliculus was involved in 17 sides and nasolacrimal duct in 2 sides. Silicone intubation lasted in 14 out of 18 sides. Failure of lasting intubation was frequent in cases with longer duration of TS-1®. Lacrimation improved subjectively in 8 out of 9 cases six months after removal of silicone tube when upper and lower canaliculi were intubated. No case showed recurrence of obstruction after removal of silicone tube.

Conclusion:Lasting silicone intubation was difficult when longer canaliculus was occluded and when silicone intubation was performed after a longer interval since discontinuation of TS-1®.

Copyright © 2020, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院